CFTR and cystic fibrosis: Given the strong clinical improvements observed with ELX/TEZ/IVA treatment in CF patients ≥ 12 years of age, as well as the critical need for more effective CFTR modulation in younger patients with at least one F508del allele, recently, Zemanick et al. evaluated the safety and efficacy of ELX/TEZ/IVA in 66 children of 6–11 years of age with F/MF or F/F genotype in a 24-week open-label, multicentric, phase 3 study (VX18-445-106, NCT03691779) [72].